Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Satsuma Pharmaceuticals stock

Own Satsuma Pharmaceuticals stock in just a few minutes.

Satsuma Pharmaceuticals, Inc is a biotechnology business based in the US. Satsuma Pharmaceuticals shares (STSA) are listed on the NASDAQ and all prices are listed in US Dollars. Satsuma Pharmaceuticals employs 18 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Satsuma Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – STSA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Satsuma Pharmaceuticals share price

Use our graph to track the performance of STSA stocks over time.

Satsuma Pharmaceuticals shares at a glance

Information last updated 2021-04-23.
52-week range$3.50 - $36.11
50-day moving average $5.84
200-day moving average $5.20
Wall St. target price$8.13
PE ratio 2.2135
Dividend yield N/A (0%)
Earnings per share (TTM) $-11.81

Buy Satsuma Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Satsuma Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Satsuma Pharmaceuticals under- or over-valued?

Valuing Satsuma Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Satsuma Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Satsuma Pharmaceuticals's P/E ratio

Satsuma Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Satsuma Pharmaceuticals shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Satsuma Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -29.14%
Return on equity TTM -50.8%
Profit margin 0%
Book value $7.03
Market capitalisation $166.4 million

TTM: trailing 12 months

Shorting Satsuma Pharmaceuticals shares

There are currently 758,336 Satsuma Pharmaceuticals shares held short by investors – that's known as Satsuma Pharmaceuticals's "short interest". This figure is 1.6% up from 746,154 last month.

There are a few different ways that this level of interest in shorting Satsuma Pharmaceuticals shares can be evaluated.

Satsuma Pharmaceuticals's "short interest ratio" (SIR)

Satsuma Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Satsuma Pharmaceuticals shares currently shorted divided by the average quantity of Satsuma Pharmaceuticals shares traded daily (recently around 403370.21276596). Satsuma Pharmaceuticals's SIR currently stands at 1.88. In other words for every 100,000 Satsuma Pharmaceuticals shares traded daily on the market, roughly 1880 shares are currently held short.

However Satsuma Pharmaceuticals's short interest can also be evaluated against the total number of Satsuma Pharmaceuticals shares, or, against the total number of tradable Satsuma Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Satsuma Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Satsuma Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0366% of the tradable shares (for every 100,000 tradable Satsuma Pharmaceuticals shares, roughly 37 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Satsuma Pharmaceuticals.

Find out more about how you can short Satsuma Pharmaceuticals stock.

Satsuma Pharmaceuticals share dividends

We're not expecting Satsuma Pharmaceuticals to pay a dividend over the next 12 months.

Satsuma Pharmaceuticals overview

Satsuma Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site